Physician profile
Munzer Samad
NPI 1972581908
$2,465.72
in general payments reported to CMS, 2019-2025
25 companies · $354 in 2025
The $354 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $459 · 2020: $329 · 2021: $347 · 2022: $366 · 2023: $394 · 2024: $216 · 2025: $354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $965.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $964.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $607.74 | 2019-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $294.22 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $201.39 | 2019-2023 | Mounjaro, Jardiance |
| Sanofi-Aventis U.S. LLC | $189.20 | 2019-2023 | |
| Astrazeneca Pharmaceuticals Lp | $134.68 | 2021-2025 | Airsupra, Breztri |
| Ucb, INC. | $123.71 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $117.28 | 2019 | |
| Novartis Pharmaceuticals Corporation | $114.24 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $102.54 | 2019-2021 | |
| Exact Sciences Corporation | $98.37 | 2023-2025 | Cologuard Collection Kit |
| Biogen, INC. | $68.39 | 2021-2022 | |
| Pfizer INC. | $59.92 | 2023-2025 | |
| Amgen INC. | $57.17 | 2024-2025 | Otezla, Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $44.57 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $38.11 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $36.90 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.74 | 2023 | Jardiance |
| Scilex Pharmaceuticals INC. | $26.82 | 2019 | |
| Dexcom, INC. | $21.07 | 2023 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $20.03 | 2024 | Gvoke Hypopen |
| E.R. Squibb & Sons, L.L.C. | $19.18 | 2020 | |
| Aprecia Pharmaceuticals, LLC | $18.67 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $16.57 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.83 | 2022 | |
| Arbor Pharmaceuticals, INC. | $13.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Munzer Samad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.